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1. Introduction 
Metabolic diseases affect more than 230 million people worldwide with an expectancy to 
increase to around 350 million in the coming 25 years. It is currently the fourth leading cause 
of death by disease. The metabolic syndrome refers to a group of interrelated metabolic 
abnormalities that include disturbed glucose homeostasis, insulin resistance (IR), increased 
body weight and abdominal fat accumulation, mild dyslipidemia and hypertension. 
Individuals with the metabolic syndrome have an increased risk of cardiovascular disease 
(CVD) and Type 2 diabetes (T2D).  
Estrogens have traditionally been connected with female reproduction, however, the 
importance of these hormones in tissues outside of the reproductive system including the 
liver, bone, the cardiovascular system and brain have since been established (Gruber et al., 
2002). Estrogen and the estrogen receptors (ERs) are well-known regulators of glucose 
homeostasis and several epidemiological and prospective studies associate estrogen to 
various aspects of the metabolic syndrome (Louet et al., 2004). Postmenopausal women 
develop visceral obesity, IR and are at high risk for T2D. Treatment of healthy 
postmenopausal women with estrogen has been shown to improve insulin sensitivity and to 
lower blood glucose (Crespo et al., 2002). Furthermore, hormone replacement therapy (HRT) 
in postmenopausal women with coronary artery disease was associated with a 35% 
reduction in the incidence of T2D (Kanaya et al., 2003). Male aromatase-deficient patients, as 
well as a male patient with loss of ER┙ function, display impaired glucose metabolism, IR 
and hyperinsulinemia (Zirilli, et al. 2008). In addition, the aromatase deficient patients 
showed impaired liver functions, hepatic steatosis, and altered lipid profile (Maffei, et al. 
2004). Additional observations in rodents support the notion that estrogen mediates anti-
diabetic effects. For example, female rodents are protected against hyperglycemia, unless 
they are ovariectomized, in spontaneous rodent models of T2D. 
 Studies in knock-out mouse models have shed light on the role of estrogen and its receptors 
in rodent obesity and glucose tolerance. Mice with functional knock-out of the aromatase 
enzyme (ArKO mice) are unable to synthesize endogenous estrogen and display an obese 
and insulin resistant phenotype (Fisher et al., 1998). A similar phenotype was observed in 
mice lacking ER┙ (ER┙KO) but not in mice lacking ER┚ (ER┚KO), indicating that ER┙ is the 
major mediator for the estrogenic effects on insulin sensitivity and body weight (Heine et 
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al., 2000). Although ERα appears to be more important in relation to body weight and 
insulin sensitivity, it remains possible that ERβ also contributes in this context, particularly 
in older mice and under specific metabolic conditions (Foryst-Ludwig et al., 2008). 
2. Carbohydrate metabolism 
Carbohydrate catabolism starts with digestion in the small intestine where monosaccharides 
derived from food are absorbed into the circulation. The most important carbohydrate is 
glucose, which is metabolized by most organisms. Circulating levels of glucose are 
controlled by two hormones; insulin and glucagon. When circulating levels of glucose are 
raised, insulin is secreted by the pancreatic β cells to stimulate glucose uptake in liver, 
muscles and white adipose tissue (WAT), where excess glucose is stored as glycogen by the 
process of glycogenesis. When blood glucose levels decrease, glucagon is secreted from the 
pancreatic α cells to stimulate the breakdown of glycogen to glucose through glycogenolysis 
(see figure 1). 
 
 
Fig. 1. Regulation of glucose homeostasis. In response to glucose excess, insulin is secreted 
by the pancreatic β cells to stimulate glucose uptake and storage in muscles, liver and white 
adipose tissue (WAT). When glucose levels decrease, glucagon is secreted to stimulate 
glucose release into circulation. 
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The β cells in the pancreatic islets of Langerhans release insulin in two phases. The first is a 
rapid response to increase blood glucose levels and the second phase is a slow release that is 
triggered independently of glucose. There are several substances apart from glucose known 
to stimulate insulin release, including amino acids from dietary proteins, acetylcholine 
released from vagus nerve endings, gastrointestinal hormones and glucose-dependent 
insulinotropic peptides (reviewed by (Kieffer et al., 1996)).  
The hormone glucagon is secreted from the α cells in the pancreatic islets of Langerhans and 
promotes conversion of hepatic glycogen into glucose, which is subsequently released into 
the blood. The output of glucagon is triggered by low levels of circulating glucose (Nussey 
& Whitehead, 2001).  
IR is a physiological condition where insulin is less effective in lowering circulating glucose. 
IR in muscle and WAT reduces glucose uptake whereas hepatic IR results in reduced 
glycogen synthesis and storage and a failure of insulin to suppress glucose production and 
subsequent release into the blood (reviewed by (Benito, 2011)). IR commonly refers to the 
reduced glucose lowering effects of insulin as described above. However, other functions of 
insulin are also affected. For example, IR in adipocytes results in reduced uptake of 
circulating lipids and increased hydrolysis of stored triglycerides, which leads to elevated 
levels of circulating free fatty acids (Savage et al., 2007). High plasma levels of insulin, 
glucose and lipids due to IR are major components of the metabolic syndrome, which could 
develop into T2D. 
3. Estrogen signaling and estrogen receptors 
Estrogens are sex steroids, which stem from the common pre-cursor cholesterol. The last 
step in the synthesis of estrogen from androgens is catalyzed by the P450 enzyme 
aromatase. The three major physiological estrogens include 17β-estradiol (E2), estrone (E1) 
and estriol. The major physiological estrogen in fertile females is E2, which has a similar 
affinity for both ERs. In addition, ERs are activated by a range of synthetic ligands including 
selective estrogen receptor modulators (SERMs) such as raloxifen and tamoxifen, the ER┙ 
selective agonist propyl-pyrazole-triol (PPT) and the ER┚-selective agonist 
diarylpropionitrile (DPN) (Heldring et al., 2007).  
Estrogens exert their physiological effects through the two ER subtypes, ER┙ and ER┚, 
which are members of the superfamily of nuclear receptors. The human ESR1 gene, which is 
encoding for ERα, is located on the chromosome 6, at 6q25.1, and includes 8 exons. The ERβ 
encoding gene, ESR2, is located on chromosome 14 at 14q22–24. ERα is mainly expressed in 
reproductive tissues, kidney, bone, WAT and liver, while ERβ is expressed in the ovary, 
prostate, lung, gastrointestinal tract, bladder and the central nervous systems (CNS) 
(Matthews & Gustafsson, 2003).  
Genetic associations have been described for polymorphisms of the ESR1 gene and several 
pathological conditions related to metabolism in general, including cardiovascular diseases, 
T2D, myocardial infarction, hypertension and venous thromboembolism (Schuit et al., 2004; 
Shearman et al., 2003; Yoshihara et al., 2009). Polymorphisms of the ESR1 gene can also 
affect lipoprotein metabolism (Lamon-Fava et al., 2010). 
ESR2 polymorphisms have been associated with anorexia nervosa, bulimic disease and 
premature coronary artery disease (Eastwood et al., 2002; Nilsson et al., 2004; Peter et al., 2005). 
ERs share a common structure with the other members of the nuclear receptor family. The 
N-terminal A/B domain is the most variable region with less than 20% amino acid identity 
between the two ERs and confers subtype specific actions on target genes. This region 
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harbors the activation function-1 (AF-1), which is ligand-independent and shows promoter- 
and cell-specific activities. The centrally located C-domain harbors the DNA binding 
domain (DBD), which is involved in DNA binding and receptor dimerization. This domain 
is highly conserved between ERα and ERβ with 97% amino acid identity. The D-domain is 
referred to as the hinge domain and displays low conservation between ERα and ERβ (30%). 
This domain has been shown to contain a nuclear localization signal. The C-terminal E-
domain contains the ligand-binding domain (LBD) and the two subtypes display 56% 
conservation in this region. The LBD contains a hormone-dependent activation function 
(AF-2) and also includes functions responsible for ligand binding and receptor dimerization. 
The F-domain has less than 20% amino acid identity between the two ER subtypes and the 
functions of this domain remain undefined (Zhao et al., 2008). 
 
 
Fig. 2. Structure and homology between human ERα and ERβ. The A/B domain is 
referring to the ligand independent transcription activation function-1 (AF-1). The C domain 
is mediating DNA binding and the D domain represents the hinge domain, which harbors 
nuclear localization signals. The E domain is involved in ligand binding and contains the 
ligand dependent AF-2 function, which is involved in ligand binding. Depicted is also the 
homology in percent between the various domains between the two subtypes. 
Like other nuclear receptors, ligand-bound ERs act as dimers to regulate transcriptional 
activation. Full transcriptional activity of the ERs is mediated through a synergistic action 
between the two activation domains, AF-1 and AF-2. Both ERα and ERβ contain a potent 
AF-2 function, but unlike ERα, ERβ seems to have a weaker corresponding AF-1 function 
and depends more on the ligand-dependent AF-2 for its transcriptional activation function 
(Dahlman-Wright et al., 2006). In their unliganded state, ERs are associated with protein 
complexes of heat shock proteins, which inhibit their functions.  
The classical estrogen signaling occurs through a direct binding of ligand activated ER 
dimers to estrogen-responsive elements (EREs) in the regulatory regions of estrogen target 
genes followed by activation of the transcriptional machinery at the transcription start sites 
of regulated genes. Estrogen also modulates gene expression by a second mechanism in 
which ERs interact with other DNA bound transcription factors, such as activating protein-1 
(AP-1) and stimulating protein-1 (Sp-1) to regulate gene expression, through a process 
referred to as transcription factor cross-talk. Estrogen may also elicit effects through non-
genomic mechanisms, which involve the activation of downstream signaling cascades like 
protein kinase A (PKA), protein kinase C (PKC) and mitogen-activated protein (MAP) 
kinase via membrane-localized ERs. 
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Recently, an orphan G protein-coupled receptor (GPR) 30 in the cell membrane was 
reported to mediate non-genomic and rapid estrogen signaling (Revankar et al., 2005; 
Thomas et al., 2005). GPR30 is structurally unrelated to ERα and ERβ and the rapid effects 
from stimulation of this receptor include release of intracellular Ca2+ and subsequent 
activation of calcium-calmodulin-dependent kinases or activation of MAP kinase and 
phosphoinositide 3-kinase pathways. Human GPR30 is located on chromosome 7p22.3, and 
is composed of three exons. Exon3 constitutes the amino acid coding region of GPR30. Based 
on genetic linkage analysis, the region of the chromosome containing GPR30 is thought to 
be related to familial hypertensive disease in humans (Lafferty et al., 2000). The mRNA for 
GPR30 appears to be expressed in most tissues. 
 
 
Fig. 3. Estrogen signaling mechanisms. I. Classical pathway involving activation of the ERs 
followed by DNA binding. II. Non-classical pathway involving interactions with 
transcription factors and subsequent indirect DNA binding. III. Non-genomic pathway 
involving GPR30.  IV. Ligand-independent pathway involving kinase cascades and 
subsequent ER phosphorylation. 
4. Estrogen signaling in glucose homeostasis 
Estrogen and estrogen signaling have long been known to be important regulators of 
glucose homeostasis and are implicated in maintaining normal insulin sensitivity. 
Fluctuations in estrogen levels below the physiological range, as a consequence of 
menopause or ovariectomy, may promote IR and T2D. In humans, the most consistent 
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effects of oral contraceptives or HRT are decreased levels of fasting plasma glucose and 
improved glucose tolerance. Absence of estrogen signaling in men, due to deficiency of the 
aromatase enzyme or ER┙, results in impaired glucose metabolism. It has also been shown 
that polymorphisms in the ER┙ gene are associated with development of the metabolic 
syndrome and T2D (Yoshihara et al., 2009).  
Estrogens further display inhibitory effects on maltase, sucrose and lactase activities in the 
intestine. Estrogen supplements have been shown to manifest a range of disaccharidase 
and lipase inhibitory actions that help to delay the absorption of dietary carbohydrates in 
the intestine, which will lead to suppression of the increased glucose levels observed after 
meals (Hamden et al., 2011). 
Several rodent studies link estrogen to glucose regulatory effects. Female rodents are 
protected against hyperglycemia, unless they are ovariectomized, in spontaneous rodent 
models of T2D and ArKO mice display severe IR (Jones et al., 2000). ER┙ and ER┚ have both 
been suggested to be involved in blood glucose homeostasis. ER┙KO mice are insulin 
resistant and ER┙ has been shown to be involved in regulation of glucose metabolism by 
acting in different tissues including liver, skeletal muscle, adipose tissue, endocrine 
pancreas and the central nervous system (CNS) as depicted in figure 4. Although ERα 
appears to be more important in relation to body weight and insulin sensitivity, it remains 
possible that ERβ also contributes in this context, particularly in older mice and under 
specific metabolic conditions. 
 
 
Fig. 4. Estrogen influences glucose metabolism in the central nervous system (CNS), 
pancreatic β cells, muscles, liver and adipocytes. 
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4.1 ERs and the role of the central nervous system in glucose homeostasis 
The first finding supporting that the central nervous system (CNS) was involved in the 
regulation of glucose homeostasis was that ruptures in the fourth ventricle resulted in 
glucosuria. This initial study was followed by numerous other studies and it is now firmly 
established that the CNS regulates glucose homeostasis through the hormones insulin, 
leptin and glucagon-like peptide (GLP)-1, as well as by glucose and fatty acids (FA). A series 
of complex systems regulate energy homeostasis in order to keep energy levels and body 
weight stable (Miller, 1982). Glucose is the vital energy source for the brain. There are 
several glucose sensing neurons in the hypothalamus, which have been established to be 
essential components in the regulation of feeding behavior and hypoglycemic counter-
regulatory responses (reviewed in (Marty et al., 2007)). The hypothalamus is subdivided 
into interconnecting nuclei, including the arcuate nucleus (ARC), paraventricular nucleus 
(PVN), ventromedial nucleus (VMN), dorsomedial nucleus (DMN) and lateral hypothalamic 
area (LHA) (Simpson et al., 2009). These central brain circuits receive signals from the 
periphery, which indicate satiety, energy levels and energy stores (Morton et al, 2006) and 
process these afferent signals to modulate food intake and energy expenditure.  
The actions of insulin have also been shown to play a direct role in the CNS since neuron-
specific insulin receptor deficient (NIRKO) mice develop mild IR and display elevated 
circulating insulin levels (Bruning et al., 2000). Injections of insulin directly into the third 
cerebral ventricle have been shown to suppress hepatic glucose production without 
effecting body weight or circulating levels of insulin (Obici et al., 2002). Further, inhibition 
of insulin or its downstream signaling pathway in the CNS, i.e. the insulin receptor and 
phosphatidylinositol-3 kinase (PI3K), impaired the ability of increased levels of insulin to 
suppress gluconeogenesis. Targeted deletion of insulin receptor expression selectively in the 
hypothalamus elicited IR in rats, which is in accordance with the results in NIRKO mice. 
These studies show that the CNS regulates glucose homeostasis through the action of 
insulin and requires intact insulin signaling pathways involving the binding of insulin to its 
receptor and subsequent activation of down-stream mediators.  
Estrogen is known to be highly relevant for the regulation of satiety, energy expenditure 
and body weight. Ovariectomy and menopause are associated with increased food intake, 
which can be reversed with estrogen replacement therapy (Eckel, 2004; Tchernof et al., 
2000). The anorectic effects of estrogen are partially mediated through actions in the 
hypothalamus as demonstrated by studies showing that direct E2 injections into the PVN 
area or the ARC/VMN of the hypothalamus effectively reduced food intake (Butera & 
Beikirch, 1989; Nunez et al., 1980). The same study also showed that the hypothalamic 
neurons, which regulate energy homeostasis, were affected by E2 administration. Energy 
homeostasis and feeding behavior controlled by the hypothalamus also follow the 
menstrual cycle and food intake in women varies across the cycle with the lowest daily food 
intake during the peri-ovulatory period when estrogen levels are peaking (Asarian & Geary, 
2006). 
ER┙ and ER┚ are both expressed in the different areas of the hypothalamus (Gillies & 
McArthur, 2010). ER┙ appears to be the major mediator of the estrogenic effects on central 
regulation of body weight by estrogens but whether this is regulated by food intake or 
actions on energy expenditure is controversial. Total ER┙ knockout mice are obese with 
increased fat accumulation in the absence of increased food intake. Targeted disruption of 
ER┙ in the VMN areas in the hypothalamus of female mice leads to weight gain, increased 
visceral adiposity, hyperphagia, hyperglycemia and impaired energy expenditure (Musatov 
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et al., 2007). ER┚ knockout mice, on the other hand, display similar food consumption 
patterns as wild-type mice (Foryst-Ludwig et al., 2008). 
4.2 ERs and the role of pancreatic β cells in glucose homeostasis 
The endocrine pancreas is an adapting tissue with the capacity to quickly respond to 
variations in the metabolic status of the organism. The ┚ cells in the islets of Langerhans 
readily adapt to peripheral IR by increasing their secretory response, as well as their cell 
mass. If ┚ cells fail to compensate, blood glucose concentration will rise to pathological 
levels and frank T2D will develop.  
Estrogenic effects on various physiological aspects of the islet of Langerhans have been 
known for a long time and estrogens are established regulators of pancreatic β cell 
functions. In humans, E2 reverses the effect of menopause on glucose and insulin 
metabolism, resulting in increased pancreatic insulin secretion, as well as improved insulin 
sensitivity (Brussaard et al., 1997; Stevenson et al., 1994). Plasma insulin levels are increased 
in pregnant rats in response to the increased levels of estrogen. Studies in mice have 
suggested that long-term exposure to E2 increased insulin content, insulin gene expression 
and insulin release without changing β cell mass. E2 has also been shown to acutely enhance 
glucose stimulated insulin secretion at physiological concentrations through the action of 
ER┙ both in vitro and in vivo (Alonso-Magdalena et al., 2008; Nadal et al., 1998).  
ER┙ has been identified as the functional predominant receptor isoform in the murine 
pancreas. E2-dependent insulin release in cultured pancreatic islets was reduced in ER┙-
deficient mice, when compared to islets derived from either ER┚-deficient or wild-type mice 
(Alonso-Magdalena et al., 2008). Also, E2, acting mainly through ER┙, has been shown to 
protect pancreatic ┚ cells from apoptosis induced by oxidative stress in mice.  
Even though ERα seems to be the dominant subtype to convey the estrogenic response in 
the pancreas, the role of ERβ might also be of importance. ER┚-deficient mice have been 
shown to display a mild islet hyperplasia and delayed first phase insulin release (Barros et 
al., 2009). 
The membrane bound estrogen-responsive GPR30 is also expressed in rodent pancreas. 
Studies using adult female GPR30-deficient mice reveal that these mice do not exhibit E2-
induced release of insulin, which is consistent with experiments using isolated pancreatic 
islet cells in vitro (Martensson et al., 2009). There are not any differences in expression of 
glucose-related genes, such as the glucose transporter (GLUT) 2 and glucokinase, in GPR30 
knockout mice when compared with wild-type mice (Martensson et al., 2009). Thus, GPR30 
may act as a regulator of insulin release after E2 stimulation. Consistent with this, GPR30 
mRNA is expressed in secretory gland cells, which may indicate that GPR30 is involved in 
insulin secretion pathways (Levin & Weissman, 2009).  
4.3 ERs and the role of the liver in glucose homeostasis 
The liver is the largest organ in the body and possesses purifying and metabolizing 
functions.  One of its most important tasks is to store glucose in the form of glycogen. The 
liver is capable of containing up to 10% of its volume as glycogen. The liver releases 
glycogen when nutrients are scarce. Liver glycogen is converted into circulating glucose in 
response to pancreatic signals; in hypoglycemic conditions glucagon is released to stimulate 
a release of hepatic glycogen. In a hyperglycemic state, the pancreas releases insulin to 
stimulate the liver to release less glucose. The maintenance of glucose homeostasis is 
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depending on whole body glucose uptake and glucose production by glycogenolysis and 
gluconeogenesis in the liver. 
Hepatic IR is impairment of insulin action in the liver, however, the mechanisms behind this 
is not completely elucidated. Hepatic IR is found in both obese non-diabetic, obese T2D 
patients and patients with non-alcoholic fatty livers. Early manifestations of hepatic IR are 
increased fasting gluconeogenesis. 
Liver abnormalities are common outcomes of obesity-related IR. Hepatic steatosis is 
primarily caused by increased hepatic free fatty acids (FFA) released from insulin resistant 
adipocytes. Due to hepatic IR, hyperinsulinemia and hyperglycemia induce de novo 
lipogenesis. Fat accumulation in adipocytes is typically followed by fat deposition in the 
liver and skeletal muscle and by subsequent development of IR in these tissues. There are 
indications showing that obesity-related IR can cause fatty liver while, vice versa, excessive 
intra-hepatic fat accumulation may promote IR and weight gain.  
Estrogens regulate liver glucose homeostasis mainly by acting via ER┙ as shown by studies 
in ER┙-deficient mice. Euglycaemic-hyperinsulinaemic clamp analysis revealed that ER┙ 
deficiency was associated with a pronounced hepatic IR as determined by the inability of 
insulin to suppress liver glucose production (Bryzgalova et al., 2008). Global gene 
expression analysis of hepatic tissue isolated from ER┙-deficient and control mice revealed 
that ER┙-deficiency was associated with increased expression of key genes involved in 
hepatic lipid biosynthesis 
 
 
Fig. 5. Schematic overview of hepatic IR. The liver responds to IR in adipose tissue with 
increased release of glucose and free fatty acids (FFAs), as well as an increased accumulation 
of triglycerides, which will cause hyperinsulinemia and hepatic steatosis. 
4.4 ERs and the role of skeletal muscle in glucose homeostasis 
Skeletal muscle accounts for 40–60% of the human body mass and is the major site of 
glucose disposal, thereby regulating whole body glucose homeostasis. Insulin-stimulated 
disposal of circulating glucose is mediated through glucose transport across the muscle cell 
surface and this step is one of the rate-limiting steps for glucose clearance. Glucose crosses 
the plasma membranes and enters the skeletal muscle through the GLUT proteins by 
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facilitated transport. Glucose clearance in response to postprandial insulin secretion is 
mainly mediated by skeletal muscle. The insulin signaling pathways inducing glucose 
uptake in skeletal muscle are well studied and involve insulin receptor, insulin receptor 
substrate (IRS), phosphatidylinositol-3 kinase (PI3-K) and AKT kinase subsequently leading 
to translocation of GLUT-4 to the cell membrane. IR in skeletal muscle is thought to be a 
primary defect in T2D (see fig. 6 for overview). 
 
 
Fig. 6. Insulin resistance in skeletal muscle cells. When insulin binds to its receptors, 
translocation of GLUT-4 to the cell membrane is triggered and glucose can readily cross the 
cell membrane by facilitated transport and be stored in the skeletal muscles. Under insulin 
resistant states, the GLUT-4 signaling is impaired, leading to decreased glucose uptake by 
the muscles. 
ER┙ and ER┚ receptors seem to have opposing effects on the expression of GLUT-4 
transporters. ER┙ was shown to induce and ER┚ seems to inhibit GLUT-4 expression in 
skeletal muscle (Barros et al., 2006). Recent studies indicate that tamoxifen-treated ER┙ 
knockout mice displayed increased GLUT-4 expression in skeletal muscle, which indicates a 
pro-diabetogenic effect of ER┚ (Barros et al., 2009). It appears that both ER isoforms 
determine the metabolic estrogen actions in skeletal muscle with ER┙ mediating protective 
actions and ER┚ deleterious.  
4.5  ERs and the role of adipose tissue in glucose homeostasis 
Adipose tissue is formed by mature adipocytes, pre-adipocytes, immune cells, extracellular 
matrix and vascular endothelium. Under normal physiologic conditions, insulin 
concentrations control within a narrow range the balance between fatty acid storage as 
triglycerides and their release into the circulation during fasting state. Adipose tissue is very 
sensitive to insulin concentrations and insulin inhibits lipolysis at concentrations that are 
much lower than those needed to inhibit hepatic glucose production or stimulate muscle 
glucose uptake. Although insulin-dependent postprandial glucose disposal in vivo is 
believed to occur mainly by uptake into skeletal muscle, insulin-enhanced glucose uptake 
into adipose tissue also contributes to whole-body glucose homeostasis.  
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There are well-documented sex differences in the pathophysiology of obesity and metabolic 
disorders. Women tend to accumulate more subcutaneous fat whereas men accumulate 
more visceral fat (Bonds et al., 2006; Crespo et al., 2002; Nuutila et al., 1995). The prevalence 
of early IR and impaired glucose tolerance seem to be higher in men than in women. 
E2 is considered an important regulator of adipose tissue development and lipid deposition 
in humans, rodents and other species. The deficiency of estrogen hormones after menopause 
or in experimental models, causes an increase in body mass and intra-abdominal adipose 
tissue leading to an android feature. The effects observed as a consequence of deficiency of 
sex steroids can be reversed by hormone replacement therapy. 
 Changes in adipose tissue distribution in women have been associated with increased risk 
of diseases and metabolic disturbances, including coronary artery disease, IR and glucose 
intolerance (Bonds et al., 2006). In obesity and T2D, there is a marked adipocyte resistance to 
the anti-lipolytic effects of insulin and the circulating FFA concentrations are typically 
elevated (Kissebah et al., 1976). Chronic over feeding induces metabolic stress and the 
adipocytes become hypertrophic and fail to proliferate and differentiate in a sufficient 
manner.  
Sex hormone programming in animals has also been shown to affect adipose tissue. A single 
postnatal injection of estradiol benzoate resulted in the development of IR, increased 
adipose tissue mass and adipocyte size in adult female rats, suggesting that postnatal ER 
activation exerts strong programming effects on metabolic processes (Alexanderson et al., 
2010). 
Stromal cells from adipose tissue have been shown to locally produce estrogens (Simpson et 
al., 2009). It is well confirmed that there is a decrease in steroid hormone-binding globulins 
in obese states in both pre- and post-menopausal women. In post-menopausal women, there 
is a direct association between estrogen levels and body mass index (BMI) (Cleary & 
Grossmann, 2009; Lukanova et al., 2004). E2 is mainly produced by the adipocytes after 
menopause through conversion of androgens or estrone and this production is not regulated 
by feedback mechanisms (Siiteri, 1987). It is suggested that this adipose-derived E2 may 
participate in the ER┙-mediated enrichment of insulin biosynthesis (Alonso-Magdalena et 
al., 2008) and in the induction of glucose stimulated insulin secretion to help the pancreatic 
┚–cells adapt to the higher demand of insulin during obesity. 
5. Concluding remarks 
Lifestyle evolution and the higher intake of high calorie diets largely contribute to the 
worldwide growing incidence of metabolic diseases. In addition to the most common 
preventive strategy based on physical activity and reduced calorie intake, identification of 
new molecular targets able to limit the development of metabolic disturbances represents 
one of the most important public health challenges. 
Estrogens have emerged as important regulators of glucose homeostasis during the last 
decades, corroborating data from clinical and experimental studies. Insulin sensitivity has 
been demonstrated to be higher in women before menopause than in age-matched men and 
postmenopausal women, which supports a beneficial effect of estrogens on insulin action 
and glucose homeostasis. It is also highly recognized that menopause promotes visceral fat 
accumulation and IR, which will ultimately lead to significantly higher risk of developing 
T2D. In addition, HRT has been reported to reverse the symptoms and to dampen the 
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incidence of T2D in postmenopausal women by 21–35% compared to women not given 
HRT.  
Effects of estrogen signaling on glucose homeostasis have been further demonstrated by 
studies showing that patients bearing genetic mutations and, thus, lack either ERα or 
aromatase expression, develop obesity, IR and impaired glucose tolerance. Genetically 
engineered mice models have confirmed these clinical observations, as ERα or aromatase 
gene deficiency similarly promotes several features of the metabolic syndrome. Taken 
together, ERα seems to play a protective role in insulin and glucose metabolism, with 
actions on the liver, adipose tissue, muscle and pancreatic β cells. In addition, ERα regulates 
food intake and energy expenditures through actions on the CNS. ERβ seems to have an 
opposing role with the potential to negatively influence insulin and glucose metabolism by 
impairing the function of adipose tissue and inhibiting the expression of GLUT4 in the 
muscle. 
Established and novel ER subtype selective ligands are valuable tools for deciphering the 
specific roles of ER┙ and ER┚ in physiology and disease. The development of novel 
treatment regimes for metabolic disease targeting ER┙ is hampered by the uterotrophic and 
mammotrophic effects of ER┙ with the major concern being the risk of developing hormone-
dependent cancer. Further studies are needed to identify and develop novel compounds 
that target estrogen signaling in selective metabolic tissues but lack the mitogenic effects in 
others, like ovaries and the breast. 
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